HIV envelope protein gp41 (519-541): the amino terminal peptide of HIV envelope protein gp41; lyses human erythrocytes and CD4+ lymphocytes
ID Source | ID |
---|---|
PubMed CID | 16132114 |
MeSH ID | M0205599 |
Synonym |
---|
hiv envelope protein gp41 (519-541) |
128631-86-7 |
l-serinamide, l-alanyl-l-valylglycyl-l-isoleucylglycycl-l-alanyl-l-leucyl-l-phenylalanyl-l-leucylglycyl-l-phenylalanyl-l-leucylglycyl-l-alanyl-l-alanylglycyl-l-seryl-l-threonyl-l-methionylglycyl-l-alanyl-l-arginyl- |
l-alanyl-l-valylglycyl-l-isoleucylglycyl-l-alanyl-l-leucyl-l-phenylalanyl-l-leucylglycyl-l-phenylalanyl-l-leucylglycyl-l-alanyl-l-alanylglycyl-seryl-l-threonyl-l-methionylglycyl-l-alanyl-l-arginyl-l-serinamide |
fp-1, hiv |
l-serinamide, l-alanyl-l-valylglycyl-l-isoleucylglycyl-l-alanyl-l-leucyl-l-phenylalanyl-l-leucylglycyl-l-phenylalanyl-l-leucylglycyl-l-alanyl-l-alanylglycyl-l-seryl-l-threonyl-l-methionylglycyl-l-alanyl-l-arginyl- |
DTXSID90155952 |
Excerpt | Reference |
---|---|
" Dose-response curves indicated that their relative potency in inhibiting FP-I-induced hemolysis was approximately correlated with their previously reported anti-HIV activity." | ( Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41. Curtain, CC; Faull, K; Gordon, LM; Kirkpatrick, A; Leung, C; Mobley, PW; Waring, AJ, 1995) |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (85.71) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |